Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celularity Inc.

2.08
+0.16008.33%
Post-market: 2.130.0500+2.40%16:58 EDT
Volume:106.12K
Turnover:213.16K
Market Cap:49.81M
PE:-1.25
High:2.10
Open:2.03
Low:1.85
Close:1.92
Loading ...

Celularity Inc. Appoints Vincent LeVien as New Class II Director and Committee Member

Reuters
·
1 hour ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

THOMSON REUTERS
·
31 May

Celularity Inc. Files Amendment to 10-K Annual Report

Reuters
·
22 May

Celularity Inc. Extends Promissory Note Maturity, Issues 100,000 Shares with Piggyback Registration Rights

Reuters
·
21 May

Celularity Inc. Announces Resignation of Board Director Dean Kehler, Citing No Disagreements

Reuters
·
17 May

Celularity Inc. Advances Placental-Derived Therapies

TIPRANKS
·
14 May

Press Release: Celularity Announces Full Year 2024 Operating and Financial Results

Dow Jones
·
09 May

Celularity Inc. Reports Significant Variation in Net Revenues and Maintains Investment Focus Despite Short-Term Profitability Challenges

Reuters
·
09 May

Celularity receives notice regarding non-payment of Nasdaq fees

TIPRANKS
·
26 Apr

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

THOMSON REUTERS
·
26 Apr

Celularity welcomes CMS action on Medicare LCD for skin substitutes products

TIPRANKS
·
14 Apr

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

GlobeNewswire
·
14 Apr

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

GlobeNewswire
·
07 Apr

BRIEF-Celularity Files For Non-Timley 10-K - SEC Filing

Reuters
·
01 Apr

BRIEF-Celularity enters into standby equity purchase agreement with Ya Ii Pn

Reuters
·
22 Mar

Celularity: on March 13, 2024, Co Entered Into Standby Equity Purchase Agreement With Ya Ii Pn, Ltd

THOMSON REUTERS
·
22 Mar

Celularity- Co Enters Agreement to Sell up to $10 Mln Stock - SEC Filing

THOMSON REUTERS
·
22 Mar

Celularity Inc - Extends Note Maturity Date to May 12, 2025 - SEC Filing

THOMSON REUTERS
·
22 Mar

Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft

TIPRANKS
·
25 Feb

Celularity Receives FDA Tissue Reference Group Recommendation Letters for Its Natalin and Acelagraft™ Wound Care Products

THOMSON REUTERS
·
25 Feb